XGEVA Improves Metastasis-Free Survival In Castrate-Resistant Prostate Cancer
Cancer Care Cost To Jump by 27 Percent In a Decade, Reaching $158 Billion in 2020
Lilly Suspends Phase III Trial Of Tasisulam in Melanoma
Genomic Health Presents Meta-Analyses of Oncotype DX
In Phase II Study, NKTR-102 Shows Objective Response
Iniparib Plus Chemo Shows Benefit In Phase II Study
ColoPrint Improves Prognosis In Stage II and III Colon Cancer
Test May Identify Predictors For Recurrence Post-Surgery
Tissue of Origin Test Consistent With Diagnosis In Blinded Validation Study
Clinical Trials Approved By NCI CTEP Last Month
FDA Approves SNDA For Gardasil For Anal Cancer And Precancerous Lesions
Trending Stories
- Lei Zheng named executive director of Mays Cancer Center
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”
“All research now involves data science at some level.”